24 May 2013
Transaction in Own Shares |
23 May 2013
Block Listing Six Monthly Return |
23 May 2013
Transaction in Own Shares |
21 May 2013
Transaction in Own shares |
17 May 2013
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting |
16 May 2013
Transaction in Own shares |
09 May 2013
Shire Wins Patent Trial Against Watson concerning LIALDA® |
09 May 2013
Transaction in Own Shares |
08 May 2013
Purchase of Shares by Employee Benefit Trust |
08 May 2013
Transaction in Own Shares |
07 May 2013
Transaction in Own Shares |
03 May 2013
Director’s Share Dealings |
03 May 2013
Transaction in Own Shares |
02 May 2013
New Chief Executive reports Q1 results and sets out strategy for growth |
02 May 2013
Transaction in Own Shares |
01 May 2013
Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Children and Adolescents with ADHD |
01 May 2013
Total Voting Rights |
30 Apr 2013
Results of the 2013 Annual General Meeting (40KB PDF) |
30 Apr 2013
Transaction in Own Shares |
29 Apr 2013
Director Declaration |
26 Apr 2013
Transaction in Own Shares |
25 Apr 2013
Shire Settles All Pending Litigation with Actavis and Watson concerning INTUNIV® |
25 Apr 2013
Transaction in Own Shares |
24 Apr 2013
BRAVE Awards Now Accepting Nominations |
24 Apr 2013
Transaction in Own Shares |
23 Apr 2013
New Expert White Paper recommends framework for action to tackle impact of ADHD on individuals, families and society |
23 Apr 2013
Transaction in Own Shares |
22 Apr 2013
Shire Regenerative Medicine Joins the American Diabetes Association by Sponsoring the 2013 San Diego Tour de Cure® Cycling Event |
19 Apr 2013
Transaction in Own Shares |
18 Apr 2013
First quarter 2013 results date notification – May 2, 2013 |
18 Apr 2013
Block Listing Application |
18 Apr 2013
Transaction in Own Shares |
16 Apr 2013
Transaction in Own Shares |
12 Apr 2013
Transaction in Own Shares |
11 Apr 2013
Transaction in Own Shares |
10 Apr 2013
Transaction in Own Shares |
09 Apr 2013
Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases |
09 Apr 2013
Transaction in Own Shares |
05 Apr 2013
Transaction in Own Shares |
04 Apr 2013
Shire Regenerative Medicine Initiates Two Phase 2 Studies Evaluating SRM003 (VASCUGEL®) in Patients with End-Stage Renal Disease Undergoing Arteriovenous Access Creation for Hemodialysis |
03 Apr 2013
Transaction in own shares |
02 Apr 2013
Director/PDMR Share Dealings |
02 Apr 2013
Total Voting Rights |
02 Apr 2013
Director/PDMR Shareholding |
28 Mar 2013
2012 Annual Report – DTR 6.3.5 Disclosure |
28 Mar 2013
Transaction in Own Shares |
27 Mar 2013
Transaction in Own Shares |
26 Mar 2013
Transaction in Own Shares |
25 Mar 2013
DERMAGRAFT® now available in Canada for the treatment of Diabetic Foot Ulcers |
25 Mar 2013
Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology |
25 Mar 2013
Transaction in Own Shares |
22 Mar 2013
Transaction in Own Shares |
20 Mar 2013
Director Declaration |
20 Mar 2013
Transaction in Own Shares |
19 Mar 2013
Transaction in Own Shares |
15 Mar 2013
Transaction in Own Shares |
13 Mar 2013
Transaction in Own Shares |
12 Mar 2013
Shire Acquires Premacure AB |
12 Mar 2013
Transaction in Own Shares |
07 Mar 2013
Transaction in Own Shares |
06 Mar 2013
Transaction in Own Shares |
05 Mar 2013
Block Listing Application |
04 Mar 2013
PDMR Share Dealings |
01 Mar 2013
PDMR Share Dealings |
01 Mar 2013
Elections for Interim Dividend in Respect of the Six Months to December 31, 2012 |
01 Mar 2013
Total Voting Rights |
01 Mar 2013
Transaction in Own Shares |
28 Feb 2013
Shire Supports Rare Disease Day 2013 |
28 Feb 2013
Transaction in Own Shares |
26 Feb 2013
Transaction in Own Shares |
22 Feb 2013
Transaction in Own Shares |
20 Feb 2013
Transaction in Own Shares |
19 Feb 2013
Shire’s VPRIV® Wins First Ever “Novel Treatment Award” from Lysosomal Disease Network at their 9th WORLD Symposium |
18 Feb 2013
Transaction in Own Shares |
15 Feb 2013
Transaction in Own Shares |
14 Feb 2013
Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013 |
13 Feb 2013
Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications |
13 Feb 2013
Transaction in Own Shares |
12 Feb 2013
Elvanse® (lisdexamfetamine dimesylate) Receives UK Marketing Authorisation, Providing a New Option for the Treatment of ADHD in Children and Adolescents in the UK |
11 Feb 2013
Transaction in Own Shares |
08 Feb 2013
Shire and Impax Settle Litigation Concerning Supply of Adderall XR Authorized Generic |
08 Feb 2013
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa |
07 Feb 2013
Transaction in Own Shares |
05 Feb 2013
Transaction in Own Shares |
01 Feb 2013
Shire reaches agreement in principle with U.S. Government |
01 Feb 2013
Full Year 2012 results date notification – February 14, 2013 |
01 Feb 2013
Total Voting Rights |
01 Feb 2013
Transaction in Own Shares |
31 Jan 2013
Transaction in Own Shares - Correction |
31 Jan 2013
Transaction in Own Shares |
29 Jan 2013
Transaction in Own Shares |
25 Jan 2013
Transaction in own shares |
23 Jan 2013
Transaction in own shares |
21 Jan 2013
Transaction in Own Shares |
17 Jan 2013
Transaction in Own Shares |
16 Jan 2013
Transaction in Own Shares |
15 Jan 2013
Shire Launches Educational Resources for Individuals with ADHD, Their Families, and Health Care Professionals |
14 Jan 2013
Transaction in Own Shares |
10 Jan 2013
Transaction in Own Shares |
09 Jan 2013
Transaction in Own Shares |
08 Jan 2013
Guidance Update |
08 Jan 2013
Shire Acquires Lotus Tissue Repair, Inc. |
07 Jan 2013
Transaction in Own Shares |
04 Jan 2013
Transaction in Own Shares |
03 Jan 2013
Transaction in Own Shares |
02 Jan 2013
Total Voting Rights |
